NDA For Cold-fX Could Follow Trial On Treating Cancer-Related Infections

CV Technologies would consider submitting a new drug application for its American ginseng extract following a National Cancer Institute-sponsored phase III trial on the effects of the ingredient on acute respiratory infection in certain leukemia patients

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet